Synergistic targeting of senolytic and senomorphic action with dual-engineered biomimetic macrophage nanovesicles for mitigating osteoarthritis

A dual-engineered nanoplatform (BS@MD) enhances joint retention and reduces cartilage degradation in mouse models of osteoarthritis.

• Senescent chondrocytes contribute to the inflammatory environment in osteoarthritis through a harmful secretory phenotype.
• BS@MD acts as a 'nanosponge' that neutralizes pro-inflammatory factors found in the osteoarthritis microenvironment.
• The nanoplatform facilitates a shift of inflammatory M1 macrophages to a more protective M2 state.
• Targeting senescent chondrocytes allows BS@MD to release therapeutic agents that may induce apoptosis in these cells.
• The approach aims to disrupt the cycle of senescence and inflammation associated with osteoarthritis.

AI simplified